- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00823381
Effect of Resvida, a Comparison With Calorie Restriction Regimen (Resvida)
Effect of Resvida(tm) Dietary Supplementation on Muscle Gene Expression: A Comparison With Calorie Restriction Regimen
The purpose of this study is to compare the effects of the antioxidant "resveratrol" to a diet intervention (Calorie Restriction) to determine how each of them affects the following: gene expression profile, cholesterol (lipids), how well the hormone insulin works to control your blood sugar, and other blood and tissue markers of metabolic and cardiovascular health.
Resveratrol is found in grape skin, wine, peanuts, and mulberries and is thought to have health benefits such as improving fat metabolism, insulin action, and possibly extending lifespan. Resvida™ is the name for the dietary supplement containing the natural antioxidant "resveratrol". Resvida™ will be supplied by DSM Nutritional Products, Ltd.
Resvida™ is considered a dietary supplement, and therefore it is not an approved drug by the Food and Drug Administration (FDA). It is regulated like a food. The U.S. Food and Drug Administration does not strictly regulate herbs and dietary supplements. The makers of Resvida™ make no claim that this supplement is meant to treat any ailment.
Calorie restriction (CR) is a low calorie diet (about 30% fewer calories than the American Dietetic Association (ADA) recommends). Calorie restriction has also been linked to health benefits (enhanced cardiovascular and metabolic health) and an extended lifespan.
This study is designed to compare the health benefits of both resveratrol and CR and to determine if resveratrol mimics some of the health benefits shown with CR.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Post-menopausal females (at least 1 year since last spontaneous menstrual bleeding)
- Caucasian
- Weight (defined as BMI): ≥ 20kg/m2 and < 30 kg/m2.
- Subjects willing and able to give written informed consent and to understand, to participate and to comply with the study requirements with specific agreement to a measurement of global gene expression profiles
- Subjects with the ability to comprehend and complete forms in English
- Subjects who are likely to comply with study procedures
- Subjects who are willing to be assigned to the Resveratrol or CR or Placebo intervention
Exclusion Criteria:
- History of serious or unstable medical or psychiatric disorders (e.g. diabetes, metabolic, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, immune, hepatic, renal, urologic, musculoskeletal, or cancer) that, in the opinion of the investigator, would make the candidate ineligible for the study.
- History of major abdominal, thoracic or non-peripheral vascular surgery within one year prior to the randomization date
- Subjects with any allergic reaction or sensitivity to grape products or any component of the test article
- Subjects who are allergic to lidocaine
- Subjects currently on a low-calorie diet, a weight control or maintenance program, or those who practice a vegetarian or vegan diet
- Subjects who engage in programmed exercise > 2 hours total per week
- Subjects who are smoking or stopped smoking within the past 6 months
- Subjects who have lost or gained >5 kg over the past six months
- Subjects on any other clinical trial or experimental treatment within the past 3 months
- Intake of dietary supplements except vitamins and minerals
- Unwilling to restrict high resveratrol-containing foods
- Current alcohol consumption >20 grams/day
- Current use of the following medications: weight loss medications (prescription or over-the-counter), beta-blockers, steroids, anticoagulants, any other medications that, in the opinion of the investigator, may compromise the validity or safety of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
one placebo pill taken once a day with breakfast
|
|
Experimental: Resveratrol
|
one pill of resveratrol (Resvida™) 75 mg once a day with breakfast
Other Names:
|
|
Active Comparator: Calorie Restriction
|
supervised calorie restriction diet: 30% reduction in caloric intake
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
global skeletal muscle gene expression profile
Time Frame: three months
|
three months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
insulin sensitivity
Time Frame: three months
|
three months
|
|
intrahepatic triglyceride content, body composition
Time Frame: three months
|
three months
|
|
blood lipid levels, markers of inflammation and plasma hormones
Time Frame: three months
|
three months
|
|
safety and tolerability
Time Frame: three months
|
three months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Samuel Klein, M.D., Washington University School of Medicine
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2007-09-25-RESV
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
Clinical Trials on resveratrol
-
Hagar Ahmed Ali Mohammed ElzainMansoura UniversityActive, not recruiting
-
University at BuffaloKaleida HealthTerminatedObesity | Insulin Resistance | Type 2 DiabetesUnited States
-
Bernard FiorettiCompleted
-
MaineHealthAmerican Heart AssociationActive, not recruitingCoronary Artery Disease | Diabetes Mellitus, Type 2United States
-
Jupiter Orphan Therapeutics Inc.National Institute on Aging (NIA)CompletedPharmacokinetics | Food-drug Interaction | SafetyUnited States
-
Maastricht University Medical CenterDSM Nutritional Products, Inc.Completed
-
University of FloridaCompleted
-
Khoo Teck Puat HospitalNational Medical Research Council (NMRC), SingaporeCompleted
-
Albert Einstein College of MedicineAmerican Diabetes AssociationCompletedImpaired Glucose ToleranceUnited States
-
Federal University of Rio Grande do SulCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.Completed